Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$0.91 - $2.01 $11,375 - $25,124
-12,500 Reduced 25.0%
37,500 $38,000
Q1 2022

Apr 19, 2022

BUY
$1.22 - $2.03 $61,000 - $101,499
50,000 New
50,000 $89,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.6B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Graypoint LLC Portfolio

Follow Graypoint LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graypoint LLC, based on Form 13F filings with the SEC.

News

Stay updated on Graypoint LLC with notifications on news.